US to loosen marijuana rules in major shift for $47 billion industry By Reuters

The U.S. Justice Department said it will move quickly to reclassify marijuana as less dangerous and immediately loosen restrictions on some cannabis products, a major federal policy shift that could lower research barriers, ease tax burdens and improve access to funding. The move is expected to benefit U.S. cannabis operators including Canopy Growth, Tilray Brands and Trulieve Cannabis, though shares initially jumped 6% to 13% before reversing as investors focused on the limited immediate scope. The broader cannabis market is projected to top $47 billion in legal sales in 2026.

Analysis

This is a material de-risking event for the U.S. plant-touching names because the biggest near-term change is not retail demand, but capital access and tax leakage. Lower scheduling friction should improve bankability for operators that have been structurally starved of plain-vanilla credit, and that matters most for balance-sheet-stressed names with refinancing needs over the next 6-18 months. The first-order equity move may fade, but the second-order effect is a lower cost of capital for the entire sector, which can re-rate terminal value even before any federal legalization.

The market is likely underestimating the competitive skew: larger multi-state operators with stronger compliance infrastructure and adjacent pharma ambitions should capture disproportionate benefit versus smaller operators that simply get a sentiment pop. Any company with a credible R&D story into pain, anxiety, or FDA-linked formulations gains an option value bump, while pure-play retail/flower operators get less. The biggest losers are illicit-market operators and overlevered private peers that relied on banking scarcity to keep the competitive field fragmented.

The contrarian risk is that this headline overstates what changes for earnings in the next quarter. If the June process drags or produces only incremental rescheduling without broader 280E relief, the P&L impact can disappoint and the sector can retrace sharply, especially after a crowded squeeze. The trade works best as a months-long policy convexity position, not a one-day momentum bet, with upside concentrated in names that can actually finance growth rather than merely survive it.

Key Decisions for Investors

• Long TLRY vs. short a basket of highly levered cannabis names on a 3-6 month horizon: TLRY has more embedded optionality on rescheduling and pharma adjacency, while weaker peers may not monetize the policy shift before the market gives back the first move.
• Accumulate CGC only on pullbacks, not strength, over the next 2-4 weeks: it should benefit from lower financing friction, but the risk/reward is still dominated by execution and dilution risk, so size as an event-driven optionality trade rather than a core long.
• Buy 3-6 month call spreads in TLRY or CGC into weakness ahead of the June 29 proceedings: the setup is asymmetric if the process expands to broader rescheduling, but premium should be defined because the first reaction can overstate near-term earnings impact.
• Avoid chasing the first 1-2 day spike; instead look for a post-event consolidation to add: this is a policy rerating story, and the better entry is when implied optimism resets while the regulatory path remains intact.
• Watch for financing announcements, refinancing, or ATM activity over the next 30-90 days: any ability to extend maturities at better terms is the real catalyst that can turn a sentiment rally into a sustained multiple expansion.